Diagnosis and treatment of iron deficiency in chronic heart failure

Iron deficiency (ID) is a common comorbidity in heart failure (HF), affecting 55% of chronic and up to 80% of acute HF patients, regardless of ejection fraction (EF). An ID is associated with reduced quality of life, impaired exercise capacity (VO<sub>2</sub> peak), higher hospitalization rate and lower survival rate. It is also an independent predictor of HF outcomes. This consensus statement critically reviews the diagnostic criteria for ID in HF and provides recommendations for their use. The efficacy and safety of intravenous iron supplements, including ferric carboxymaltose (FCM) and ferric derisomaltose (FDI), are analyzed highlighting the indications and potential adverse effects. Key clinical trials and guideline recommendations are summarized. In summary, the document addresses the diagnostics, treatment and monitoring of ID in HF.

Authors

Institutions

Publication Details

Journal
Wiener klinische Wochenschrift
Published
2025-05-01
DOI
https://doi.org/10.1007/s00508-025-02521-x
Citations
2
Primary Topic
Erythropoietin and Anemia Treatment
Type
article
Field-Weighted Citation Impact
3.54
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Diagnosis and treatment of iron deficiency in chronic heart failure

Anna Rab, Rudolf Berger, Peter P. Rainer, Christopher Adlbrecht et al.
2 citations
Wiener klinische Wochenschrift
Erythropoietin and Anemia Treatment
3.54
article

Diagnosis and treatment of iron deficiency in chronic heart failure

Anna Rab, Rudolf Berger, Peter P. Rainer, Christopher Adlbrecht, Martin Hülsmann, Gerhard Pölzl, Johann Altenberger, Johann Auer, Moritz Messner, Christian Ebner, Jakob Dörler, Deddo Mörtl, Marc‐Michael Zaruba, Robert Berent, Thomas Weber, Friedrich Fruhwald
article en
2 citations

Abstract

Iron deficiency (ID) is a common comorbidity in heart failure (HF), affecting 55% of chronic and up to 80% of acute HF patients, regardless of ejection fraction (EF). An ID is associated with reduced quality of life, impaired exercise capacity (VO<sub>2</sub> peak), higher hospitalization rate and lower survival rate. It is also an independent predictor of HF outcomes. This consensus statement critically reviews the diagnostic criteria for ID in HF and provides recommendations for their use. The efficacy and safety of intravenous iron supplements, including ferric carboxymaltose (FCM) and ferric derisomaltose (FDI), are analyzed highlighting the indications and potential adverse effects. Key clinical trials and guideline recommendations are summarized. In summary, the document addresses the diagnostics, treatment and monitoring of ID in HF.

Wiener klinische WochenschriftVol. 137(S3)
Innsbruck Medical University (AT), Medical University of Graz (AT), Music and Arts University of the City of Vienna (AT), Klinikum Klagenfurt (AT), University of Applied Sciences Burgenland (AT), St. Josefs Hospital (DE), BioTechMed-Graz (AT), Tirol Kliniken (AT), Klinikum Wels-Grieskirchen (AT), Krankenhaus der Elisabethinen (AT), MAS Alzheimerhilfe (AT), Schwarzwald-Baar Klinikum (DE), LungenClinic Grosshansdorf (DE), Karl Landsteiner University of Health Sciences (AT), Medical University of Vienna (AT)
Good health and well-being
Openalex Percentile: Top 8%
Erythropoietin and Anemia Treatment
3.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.